Message from the Governor General on Mental Health Week
OTTAWA, ON, May 6, 2024 /CNW/ - Mental health issues can impact anyone, at any point in their lives, and can present in many different ways. In any given year, it can affect one in five Canadians, from all walks of life, all cultures, all identities and all backgrounds. And when our mental health suffers, so does our physical health.
As we mark the beginning of Mental Health Week, I hope we can embody this year's theme, "a call to be kind." We need to show kindness and compassion, which can make a big difference for those struggling with their mental health. When we demonstrate understanding and empathy?by forging relationships, building trust or just listening without judgement?we can have a direct influence over someone's mental health.
This week is a reminder that we have a collective responsibility to choose kindness throughout the year. To everyone struggling, whether openly or in silence, know that you are never alone.
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024).
The campaign focuses on access to IBD care and treatment as the burden of...
On Wednesday, May 15, Red Door Community hosted their annual Celebrating Women Working and Living with Cancer Luncheon at the Metropolitan Club in New York City. The event raised more than $300,000 while shining a light on the women who inspire us...
Product: Kalihim (Philippine Bread Roll)
Issue: Food - Allergen - Egg
Distribution: British Columbia
See the affected products and product photos for this recall
SOURCE Canadian Food Inspection Agency (CFIA)
The global industrial automation market in life sciences industry size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 11.4% during the forecast period. ...
Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRMtm System,* the first modular cardiac rhythm management (CRM) system that consists of the EMBLEMtm Subcutaneous...
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...